Tarsus Pharmaceuticals, Inc. TARS Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s accrued expenses?
- Tarsus Pharmaceuticals, Inc. (TARS) reported accrued expenses of $8.53M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s accrued expenses changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s accrued expenses decreased by 14.1% year-over-year, from $9.93M to $8.53M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s accrued expenses has grown at a 76.4% compound annual growth rate (CAGR), from $1.04M to $17.78M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.